Compare Strategy Inc. (MSTR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs TransMedics Group Inc — how do they compare? Strategy Inc. trades at $154.41 (market cap $60.40B), while TransMedics Group Inc trades at $78.41 (market cap $2.74B). The key difference: Strategy Inc. is far larger — about 22× TransMedics Group Inc's market cap, and Strategy Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and TransMedics Group Inc for 24 Days on average.
| MSTR | TMDX | |
|---|---|---|
Market Cap | $60.40B | $2.74B |
Volume | 23,421,830 | 949,331 |
Sector | Technology | Health |
52-Week High | $320.29 | $150.42 |
52-Week Low | $82.31 | $61.99 |
Typical Hold Time | 112 Days | 24 Days |
Enterprise Value | $79.16B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $155.91, up 1.66% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $3.85 billion in 2025 on $477.23 million in revenue, with a negative net income margin of -806.35%. Recent news highlights Bitcoin's price surge and Citigroup raising its price target to $240, though the stock has shown volatility around Bitcoin price movements.
The outlook is polarized: analyst consensus is bullish with a $253.36 price target, but fundamental risks are high due to persistent losses, negative cash flow from operations, and heavy debt. Investment opportunity hinges on Bitcoin's performance, while risks include earnings misses and financial instability.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
